论文部分内容阅读
目的:研究益宫胶囊的体内抗肿瘤作用。方法:建立小鼠S180实体瘤、S180腹水型肿瘤及环磷酰胺致小鼠免疫抑制模型,观察益宫胶囊对模型鼠的抑瘤率、生命延长率、抗瘤药物的增效作用及对免疫抑制小鼠胸腺、脾脏重量及血清IgG水平的影响。结果:益宫胶囊1.6,3.0,5.0g.kg-1单用对S180实体瘤的抑制率分别为20.99%,26.54%,35.98%,对S180腹水型肿瘤小鼠存活时间的延长率分别为5.15%,11.85%,35.15%。益宫胶囊1.6,3.0,5.0g.kg-1与环磷酰胺20mg.kg-1合用时对S180实体瘤的抑制率分别为29.44%,38.79%,44.39%,与氟尿嘧啶15mg.kg-1合用时对S180腹水型肿瘤小鼠存活时间的延长率分别为14.12%,22.70%,41.42%。益宫胶囊可显著提高免疫抑制小鼠胸腺、脾脏重量指数及血清IgG含量(P<0.05)。结论:益宫胶囊可显著抑制小鼠肿瘤生长,并可增强环磷酰胺、氟尿嘧啶的抗肿瘤作用,同时可缓解磷酰胺引起的小鼠免疫功能抑制。
Objective: To study the anti-tumor effects of Yigong capsules in vivo. METHODS: Mouse S180 solid tumor, S180 ascitic tumor and cyclophosphamide-induced mouse immunosuppressive model were established. The anti-tumor rate, life prolonging rate, synergistic effect of anti-tumor drugs and immunosuppression of Yigong Capsule on model mice were observed. Inhibition of mouse thymus, spleen weight and serum IgG levels. RESULTS: The inhibitory rates of Yigong Capsules 1.6, 3.0, 5.0 g.kg-1 alone on S180 solid tumors were 20.99%, 26.54%, 35.98%, respectively. The survival rate of mice with S180 ascites tumor was 5.15, respectively. %, 11.85%, 35.15%. The inhibition rate of solid tumors of S180 with Yigong Capsules 1.6,3.0,5.0g.kg-1 and cyclophosphamide 20mg.kg-1 was 29.44%, 38.79%, 44.39%, respectively, and combined with fluorouracil 15mg.kg-1. The survival rates of the mice with S180 ascite tumors were 14.12%, 22.70%, and 41.42%, respectively. Yigong Capsule can significantly increase the weight index of thymus and spleen and serum IgG in immunosuppressed mice (P<0.05). Conclusion: Yigong capsule can significantly inhibit the growth of mice and enhance the anti-tumor effect of cyclophosphamide and fluorouracil. At the same time, it can alleviate the inhibition of immune function in mice induced by phosphoramide.